Welcome to our dedicated page for Charles River Laboratories International news (Ticker: CRL), a resource for investors and traders seeking the latest updates and insights on Charles River Laboratories International stock.
Founded in 1947, Charles River Laboratories International, Inc. (symbol: CRL) is a global leader in providing essential products and services to pharmaceutical and biotechnology companies, government agencies, and academic institutions. The company's mission is to accelerate research and drug development efforts, significantly contributing to the healthcare industry.
Charles River operates through three main segments:
- Research Models & Services: This segment is renowned for being the leading provider of laboratory animal models. Charles River breeds and supplies animals with specific genetic traits for preclinical studies worldwide, supporting the critical early stages of drug discovery.
- Discovery & Safety Assessment: This segment offers a comprehensive range of services necessary for the early development of new drugs. From discovery services to safety assessments, Charles River helps clients navigate the complex process of taking a drug from concept to early-stage development.
- Manufacturing Support: This includes microbial solutions for in vitro testing, biologics testing services, and avian vaccine services. These services are integral to ensuring the safe manufacture and quality control of new therapies.
The company's workforce is dedicated to providing clients with the expertise and services they need to improve and expedite the discovery and development of new therapies. Charles River's collaborative approach and commitment to excellence have established it as a trusted partner in the life sciences industry.
Charles River continues to innovate and expand its services, making significant strides in the fields of drug discovery, biotechnology, and pharmaceuticals. With a strong financial footing and strategic partnerships, the company is well-positioned to support the future of healthcare advancements globally.
Rhea-AI Summary
Charles River Laboratories International, Inc. (NYSE: CRL) expands its CliniPrime™ suite with the launch of CliniPrime Cryopreserved Leukopaks for gene-modified cell therapy development and manufacturing. Cryopreserved leukopaks play a critical role in research and development, maximizing cellular viability, consistency, and long-term availability. The new offering aims to meet the growing industry need for reliable and consistent sources of cellular starting material, supporting both clinical trial development and commercialization.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.06%
Tags
-
Rhea-AI Summary
Charles River Laboratories International, Inc. (NYSE: CRL) and Aitia announce a strategic partnership focused on co-developing patient-derived xenograft (PDX) Digital Twins for in vivo oncology research. Aitia will deploy Charles River's AI-powered drug solution platform, Logica, to optimize the discovery and early development of therapeutic programs for neurodegenerative disease and oncology. The agreement also includes the development of a PDX Digital Twin to predict the best tumor models for in vivo oncology research. Charles River has made an equity investment in Aitia as part of the partnership.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.14%
Tags
-
News
Rhea-AI Summary
Charles River Laboratories International, Inc. (NYSE: CRL) to Present 19 Scientific Posters at Neuroscience 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.69%
Tags
Rhea-AI Summary
CRL: Charles River Laboratories International, Inc. (NYSE: CRL) reported third-quarter revenue of $1.03 billion, with GAAP earnings per share of $1.69 and non-GAAP earnings per share of $2.72. The company updated its 2023 guidance, narrowing revenue growth to 2.5-3.5% and non-GAAP EPS estimate to $10.50-10.70.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.74%
Tags
-
Rhea-AI Summary
Charles River Laboratories introduces real-time e-commerce ordering experience for research models
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.21%
Tags
-
Rhea-AI Summary
Charles River Laboratories to release Q3 2023 financial results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.9%
Tags
Rhea-AI Summary
Charles River Laboratories offers access to a collection of 400 annotated pediatric cancer models for preclinical cancer research, in line with new regulatory guidelines requiring testing for pediatric indications. This collection will help assess the safety and efficacy of new oncology treatments for children and potentially lead to new treatment options. Charles River has extensive experience in oncology research and is well-equipped to support researchers in navigating these new guidelines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.9%
Tags
-
Rhea-AI Summary
Charles River Laboratories achieves 90% renewable electricity globally and aims for 100% by 2025. Company's energy recovery system recognized as a top project. Develops industry partnerships for sustainable initiatives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.74%
Tags
-
Rhea-AI Summary
Charles River Laboratories International, Inc. (NYSE: CRL) announced the launch of its Lentivation™ platform, reducing lentiviral vector production timelines by up to 60 percent, from 18 months to less than 7 months. The platform aims to support gene and gene-modified cell therapies with stringent quality control and optimized methods.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.58%
Tags
Rhea-AI Summary
Charles River Laboratories opens RightSource facility in the UK to provide biologics testing services to the Stevenage advanced therapies biocluster.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.03%
Tags
FAQ
What is the current stock price of Charles River Laboratories International (CRL)?
The current stock price of Charles River Laboratories International (CRL) is $187.91 as of January 9, 2025.
What is the market cap of Charles River Laboratories International (CRL)?
The market cap of Charles River Laboratories International (CRL) is approximately 9.6B.
What services does Charles River Laboratories provide?
Charles River provides research models, discovery and safety assessment services, and manufacturing support, including microbial solutions, biologics testing, and avian vaccine services.
When was Charles River Laboratories founded?
Charles River Laboratories was founded in 1947.
Who are Charles River Laboratories' primary clients?
The company's primary clients are pharmaceutical and biotechnology companies, government agencies, and leading academic institutions.
What is Charles River Laboratories' mission?
Charles River's mission is to accelerate research and drug development efforts globally.
What is included in the Research Models & Services segment?
This segment includes providing laboratory animal models with specific genetic traits for preclinical studies.
What does the Discovery & Safety Assessment segment offer?
This segment offers services for the early development of new drugs, including discovery services and safety assessments.
What are some of the services provided under Manufacturing Support?
Manufacturing Support includes microbial solutions for in vitro testing, biologics testing services, and avian vaccine services.
How does Charles River contribute to the healthcare industry?
Charles River helps expedite the discovery and development of new therapies, aiding in research and the safe manufacture of new drugs.
What makes Charles River Laboratories a trusted partner in the life sciences industry?
The company's commitment to excellence, innovative approach, and comprehensive service offerings make it a trusted partner.
What is the ticker symbol for Charles River Laboratories International, Inc.?
The ticker symbol for Charles River Laboratories International, Inc. is CRL.
Charles River Laboratories International, Inc.
NYSE:CRL
CRL Rankings
CRL Stock Data
9.61B
50.64M
0.92%
103.9%
4.19%
Diagnostics & Research
Services-commercial Physical & Biological Research
United States of America
WILMINGTON